Mentor's synthetic pelvic prolapse mesh:
This article was originally published in Clinica
Mentor has received US FDA 510(k) clearance to sell its first synthetic mesh product for treating pelvic organ prolapse, NovaSilk. The use of synthetic meshes for the treatment of pelvic organ prolapse represents one of the fastest growing segments of the women's health market, claimed the Santa Barbara, California firm, which already sells two human tissue-based products for the condition. NovaSilk comprises a macroporous, knitted, monofilament polypropylene mesh, while also being soft and light. It offers resistance to traction, allows tissue colonisation and facilitates positioning during surgery, the company said. According to Mentor, pelvic organ prolapse is estimated to afflict around 36 million women in the US and Europe.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.